Erratum: Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options

Antonio José Conde Moreno*, Carlos Ferrer Albiach, Rodrigo Muelas Soria, Verónica González Vidal, Raquel García Gómez and María Albert Antequera

Erratum
After the publication of this work [1], we noticed that an incorrect version of Table two (Table 1 here) [1] was published. The correct version of Table two (Table 1 here) is provided here.

Reference
1. Conde Moreno AJ et al. Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options. Radiation Oncology. 2014;9:258.
| Study | ClinicalTrials.gov Identifier | Phase | Aim | Arms | Primary Objectives | Secondary Objectives |
|-------|--------------------------------|-------|-----|------|-------------------|---------------------|
| Radiotherapy for Oligometastatic Prostate Cancer | NCT01859221 | 2 | Efficacy and safety in patients with primary active or not | 2: CR and HN | Improvement in median progression-free survival in patients with metastatic prostate cancer over historic control rates in hormone receptive and castration resistant subgroups. | Improvement in overall survival of patients with metastatic prostate cancer. |
| University of Florida | | | | | | |
| Stereotactic Radiosurgery in Treating Patients With Metastatic Breast Cancer, Non-Small Cell Lung Cancer, or Prostate Cancer | NCT02206334 | 1 | Safety Study | 1 | To determine the recommended SBRT dose for each of the metastatic locations being treated given the individual and overlapping fields when multiple metastases are treated with SBRT in a national clinical trials network setting. | Treatment failure rates in patients treated with stereotactic radiation for metastatic prostate cancer after type of secondary outcome. Quality of life in patients treated with stereotactic radiation for metastatic prostate cancer. |
| NRG Oncology Foundation, Inc. | | | | | | |
| Collaborator: NCI RTOG | | | | | | |
| Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer | NCT01558427 | 2 | Defer the start of ADT | 2: A. Active surveillance | Androgen deprivation therapy free survival. | Quality of life |
| University Hospital, Ghent | | | | | | |
| Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer | NCT02192788 | 2 | Safety and Efficacy Study | 1 | Local and symptomatic control of oligometastases treated by SBRT | Biochemical progression rates |
| GICOR | | | | | | |

Moreno et al. Radiation Oncology (2015) 10:154
Table 1 Current Ongoing trials for Prostate Cancer Oligometastases in 2014 (www.clinicaltrials.gov) (Continued)

| Collaborators: | Chemotherapy-free survival and overall survival. | Analyze toxicities and quality of life of patients before and after treatment |
|----------------|-----------------------------------------------|--------------------------------------------------|
| SBRT-SG        |                                               |                                                  |
| SEOR           |                                               |                                                  |
| Consorcio Hospitalario Provincial de Castellón |                                               |                                                  |

CR Castrate resistant, HR Hormone Receptive, NCI National Cancer Instit, RTOG Radiation Therapy Oncology Group, ADT androgen deprivation therapy
CTCAE 4.0: Common Terminology Criteria for Adverse Events SBRT-SG: Sterotactic Body Radiation Therapy Spanish Group
GICOR: Spanish Group of clinical Investigation in Radiation Oncology SEOR: Spanish society of Radiation Oncology